Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Down – Here’s Why

Shares of Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) gapped down prior to trading on Friday. The stock had previously closed at $15.90, but opened at $15.25. Ascentage Pharma Group International shares last traded at $15.2650, with a volume of 1,010 shares trading hands.

Wall Street Analysts Forecast Growth

AAPG has been the topic of several recent analyst reports. B. Riley Financial assumed coverage on shares of Ascentage Pharma Group International in a research note on Wednesday, June 10th. They set a “buy” rating and a $45.00 price objective on the stock. Raymond James Financial reiterated a “buy” rating on shares of Ascentage Pharma Group International in a research note on Wednesday, June 10th. Finally, BTIG Research reissued a “buy” rating and set a $48.00 price target on shares of Ascentage Pharma Group International in a research report on Friday, August 21st. Two research analysts have rated the stock with a Strong Buy rating and eight have given a Buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $46.43.

Ascentage Pharma Group International Price Performance

The stock’s 50-day simple moving average is $17.09 and its 200 day simple moving average is $19.64. The company has a current ratio of 1.22, a quick ratio of 1.18 and a debt-to-equity ratio of 1.09.

Ascentage Pharma Group International (NASDAQ:AAPG) last issued its quarterly earnings data on Wednesday, August 19th. The company reported ($0.65) earnings per share for the quarter. The firm had revenue of $22.24 million for the quarter. As a group, sell-side analysts anticipate that Ascentage Pharma Group International – Unsponsored ADR will post -2.42 earnings per share for the current fiscal year.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical-stage biopharmaceutical company focused on discovering and developing therapies that target mechanisms involved in programmed cell death. The company’s research is primarily directed toward cancer and other serious diseases in which regulating apoptosis may offer therapeutic benefits.

Its pipeline includes small-molecule drug candidates designed to inhibit proteins that help cancer cells survive. Key programs have included lisaftoclax (APG-2575), a BCL-2 inhibitor being investigated for hematologic malignancies, and APG-115, an MDM2-p53 inhibitor under evaluation in oncology indications.